Analysis of the Effect of Miglitol in the Treatment of Diabetes Mellitus Based on Ag+ Disinfectant Sampling Needle

The present work selected 120 patients, affected by diabetes, as control subjects in the Affiliated Hospital of Kunming Medical University. According to the principle of random distribution, two groups were established, miglitol study group (65 cases) and metformin control group (55 cases). The Ag + disinfectant sampling needle is a rapid detection tool to evaluate the efficacy of diabetes in both groups. The related biochemical indexes of the patients were measured before and after treatment at the 3rd, 6th, and 12th weeks. The test results showed that there were significant differences in fasting blood glucose value (FBG) and postprandial blood glucose value (2hFBG) among the two groups after 3-, 6-, and 12-month treatment. With the extension of treatment, the blood glucose level of diabetic patients gradually stabilized. Fasting insulin level (FINS) and postprandial two-hour insulin level (2hINS) increased gradually. At the 12th week, by measuring the HbA1c level of the patients, it was found decreasing significantly. In detail, the study group decreased more significantly than the control group, and the incidence of adverse reactions during treatment was 10.8% and 23.6%, respectively, with a significant statistical significance (P < 0 05). Meanwhile, we measured other biochemical indexes of patients from both groups after drug treatment. At the 6th week, the levels of glycosylated glycoprotein (HbA1c), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in the study group decreased more than in the control group. Therefore, miglitol shows a better hypoglycemic effect on type 2 diabetes, and the gastrointestinal adverse reactions are lesser than metformin, which is more worthy in clinical application.

Download Full-text

Antihyperglycemic and antihyperlipidemic effects of low-molecular-weight carrageenan in rats

Open Life Sciences ◽

10.1515/biol-2018-0046 ◽

2018 ◽

Vol 13 (1) ◽

pp. 379-384 ◽

Cited By ~ 1

Author(s):

Xia Qiu ◽

Wenwen Zhong

Keyword(s):

Molecular Weight ◽

Body Weight ◽

Blood Glucose ◽

High Fat Diet ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Postprandial Blood Glucose ◽

Control Group ◽

Low Molecular Weight ◽

High Fat

AbstractThis study investigated the antihyperglycemic and antihyperlipidemic effects of low-molecular-weight carrageenan (LC) on rats fed a high-fat diet. Wistar rats were divided into five groups: normal control group (NC), high-fat diet control group (HC), carrageenan-treated control group (CC), 1% LC group (1% LC), and 3% LC-groups (3% LC). Body weight, food intake, fecal weight, blood glucose, and serum lipid levels were measured. After 30 days, body weight significantly decreased in the LC-treated groups than in the HC group. Moreover, in the LC-treated groups, postprandial blood glucose, total cholesterol, triglyceride, and low-density lipoprotein cholesterol (LDL-C) levels decreased, whereas high-density lipoprotein cholesterol (HDL-C) levels increased. From this study, our data suggest that LC has antihyperglycemic and hypolipidemic effects when compared to carrageenan, likely related to its increased absorption due to its lower molecular weight.

Download Full-text

Efficacy and safety of bromocriptine quick release as an add on therapy with metformin and glipizide in type 2 diabetes mellitus patients: an open label randomized controlled study

International Journal of Basic & Clinical Pharmacology ◽

10.18203/2319-2003.ijbcp20191097 ◽

2019 ◽

Vol 8 (4) ◽

pp. 669

Author(s):

Nithyapriya M. ◽

S. Purushotaman

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Blood Glucose ◽

Fasting Blood Glucose ◽

Postprandial Blood Glucose ◽

Control Group ◽

Study Group ◽

Quick Release ◽

Type 2 Dm

Background: Type 2 Diabetes Mellitus (DM) is a metabolic disorder, treated by insulin and oral hypoglycaemic agents (OHA). Despite treatment, to protect diabetic population from its complications is difficult. So, there is a need for an OHA with different mechanism of action and minimal side effects. Bromocriptine Mesylate QR (Quick release) formulation was approved by FDA for treatment of type 2 DM. Hence, this study was planned to highlight the usefulness of Bromocriptine QR in type 2 diabetes mellitus.Methods: Total 140 patients with type 2 DM were randomized into two groups. The control group was treated with Metformin 500 mg BD (twice daily) and Glipizide 5 mg BD for a period of 3 months. The study group received Bromocriptine quick release 1.6 mg once daily, metformin 500 mg BD and Glipizide 5 mg BD for a period of 3 months. In both control and study groups, fasting blood glucose, postprandial blood glucose was monitored at 0, 1st, 2nd and 3rd month. HbA1C was done at baseline and at the end of 3 months.Results: There was statistically significant decrease in fasting blood glucose, postprandial blood glucose and HbA1C when compared to baseline in both control group (p <0.05) and study group (p <0.05) at the end of 3 months. But the decrease in FBS, PPBS, HbA1C was higher in the study group (p=0.0001) than the control group (p=0.001).Conclusions: In type 2 DM patients, Bromocriptine QR, combined with metformin and Glipizide reduced fasting and postprandial blood glucose and HbA1C significantly compared to metformin and glipizide alone.

Download Full-text

Clinical Efficacy and Safety of Yi-Shen-Hua-Shi Granule for Diabetic Kidney Disease: A Cohort Study

10.21203/rs.3.rs-113813/v1 ◽

2020 ◽

Author(s):

Yebei Li ◽

Zhipeng Yan ◽

Kang Wang ◽

Tianlun Huang ◽

Xin Liu ◽

...

Keyword(s):

Blood Glucose ◽

Kidney Disease ◽

Diabetic Kidney Disease ◽

Adverse Reactions ◽

Low Density Lipoprotein ◽

Fasting Blood Glucose ◽

Density Lipoprotein ◽

Control Group ◽

Efficacy And Safety ◽

Diabetic Kidney

Abstract Background: The present study aims to explore the relative efficacy and safety of Yi-Shen-Hua-Shi (YSHS) granule in diabetic kidney disease (DKD) patients. Methods: A total of 260 DKD patients with the urinary albumin-to-creatinine ratio (UACR) ≥ 30 mg/g and estimated glomerular filtration rate (eGFR) > 30 ml/min/1.73 m2 were included. 130 patients receiving YSHS plus irbesartan and 130 patients with irbesartan alone. The primary outcomes were included serum creatinine (Scr), 24-hour urinary protein (24h UTP), UACR, and the overall response rate (ORR). The secondary outcomes included fasting blood glucose (FBG), hemoglobin A1c (HbA1c), total cholesterol (TC), triglyceride (TG), and low-density lipoprotein (LDL-C). Results: At the end of 12 weeks, compared with the controls, the YSHS group could effectively improve the level of 24h UTP (P = 0.007), UACR (P = 0.001), FBG (P = 0.024), HbA1c (P = 0.005), TC (P = 0.018), TG (P = 0.001), and LDL-C (P = 0.034). The ORR in the YSHS group and control group was 47 % versus 30 % at 12 weeks (P = 0.005), respectively. There was no statistical difference in major adverse reactions between the two groups during treatment.Conclusions: The YSHS granule has significant curative effects on DKD, especially in reducing proteinuria, improving blood glucose and lipid metabolism, with no obvious adverse reactions.

Download Full-text

Relationship of Glycated Haemoglobin with Lipid Profile among Patients with Type 2 Diabetes Mellitus

BIRDEM Medical Journal ◽

10.3329/birdem.v7i1.31271 ◽

2017 ◽

Vol 7 (1) ◽

pp. 43-47 ◽

Cited By ~ 1

Author(s):

Tasrina Shamnaz Samdani ◽

Palash Mitra ◽

Muhammad Abdur Rahim

Keyword(s):

Type 2 Diabetes ◽

Blood Glucose ◽

Lipid Profile ◽

Significant Positive Correlation ◽

Fasting Blood Glucose ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Diabetic Patients ◽

Positive Correlation

Background: Glycated hemoglobin (HbA1c) is widely used as an index of mean glycaemia, a measure of risk for the development of diabetic complications and a measure of the quality of diabetes care. Patients with type 2 diabetes have an increased prevalence of dyslipidemia. Treatment of dyslipidaemia improves cardiovascular outcomes. The aim of this study was to determine the impact of glycemic control on lipid profile.Methods: This cross-sectional study was conducted among 300 type 2 diabetic patients admitted in BIRDEM General Hospital from November 2013 to April 2015. Fasting blood samples were collected and different lipid fractions along with fasting blood glucose and HbA1c were estimated. Pearsons correlation test was applied to evaluate the correlation between HbA1c and components of lipid profile.Results: The mean value of total cholesterol (TC), triglyceride (TG), low density lipoprotein-cholesterol (LDLC), fasting blood glucose (FBG) and HbA1c were higher and high density lipoprotein-cholesterol (HDL-C) was lower in females when compared with these values for males. HbA1c had significant positive correlation with LDL-C (p=0.045) and negative correlation with HDL-C (p=0.024). Serum lipid profile and glycaemic controls were significantly (p=0.000) better in older age group (age ? 50 years).Conclusions: Significant positive correlation of HbA1c with lipid profiles specially LDL-C suggested that HbA1c can also be used as predictor of dyslipidemia in addition to glycemic control.Birdem Med J 2017; 7(1): 43-47

Download Full-text

Clinical Observation of Miglitol Combined with Insulin in Newly Diagnosed Type 2 Diabetes Mellitus

Journal of Clinical Medicine Research ◽

10.32629/jcmr.v2i3.469 ◽

2021 ◽

Vol 2 (3) ◽

Author(s):

Shengting Huang ◽

Shiying Huang

Keyword(s):

Type 2 Diabetes ◽

Blood Glucose ◽

Insulin Glargine ◽

Adverse Reactions ◽

Fasting Blood Glucose ◽

Postprandial Blood Glucose ◽

Control Group ◽

Observation Group ◽

Newly Diagnosed

Objective — To study the clinical efficacy of miglitol combined with insulin in the treatment of newly diagnosed type 2 diabetes mellitus. Methods — 96 newly diagnosed type 2 diabetes patients admitted to our hospital from January 2021 to September 2021 were selected as the subjects of this study. They were randomly divided into two groups by drawing lots. The control group was treated with acarbose combined with insulin glargine, and the observation group was treated with miglitol combined with insulin glargine. Fasting blood glucose, 2h postprandial blood glucose, glycosylated hemoglobin (HbA1c), blood glucose compliance time, occurrence of adverse reactions and quality of life score of 2 groups were measured before and after treatment. Results — After treatment, fasting blood glucose, 2h postprandial blood glucose and HbA1c in both groups were lower than before (P < 0.05), and there was no statistical significance in the difference between the two groups and the time of blood glucose reaching the standard (P > 0.05). The incidence of adverse reactions in observation group was lower than that in control group, and the quality of life score in observation group was better than that in control group (P < 0.05). Conclusions — Miglitol or acarbose combined with insulin glargine can effectively control blood glucose in patients with newly diagnosed type 2 diabetes, but miglitol combined with insulin glargine has fewer adverse reactions, which can be used as the first choice for clinical treatment of newly diagnosed type 2 diabetes.

Download Full-text

Clinical Analysis of Targeted Navel Drops in the Treatment of Diabetes Mellitus

Journal of Clinical and Nursing Research ◽

10.26689/jcnr.v5i5.2574 ◽

2021 ◽

Vol 5 (5) ◽

pp. 194-198

Author(s):

Yueping Zhu

Keyword(s):

Blood Glucose ◽

Research Group ◽

Fasting Blood Glucose ◽

Effective Rate ◽

Postprandial Blood Glucose ◽

Control Group ◽

Diabetic Patients ◽

Group 2 ◽

And Control ◽

Group 1

Objective: To analyze and evaluate the clinical efficacy of targeted navel drops in the treatment of diabetes mellitus. Methods: The time span of the study was from September 2020 to April 2021, and 288 diabetic patients were selected from our hospital. The patients were divided into research group (n = 96) group, control group 1 (n = 96) and control group 2 (n = 96) by random number table. Control group 1 was managed with diet and exercise alone, control group 2 was treated with metformin on the basis of control group 1, and based on the treatment plan of the two control groups, the research group was treated with targeted navel drops. The relevant indexes of the three groups were compared and analyzed. Results: There was no significant difference in the fasting blood glucose and 2-hour postprandial blood glucose among the three groups (p > 0.05) before the treatment. After treatment, the fasting blood glucose and 2-hour postprandial blood glucose of the research group were significantly lower than those of control group 1 and control group 2 (p < 0.05). The total effective rate of the research group was 95.8%, that of control group 1 was 85.4%, and that of control group 2 was 79.2%. The total effective rate of the research group was significantly higher than that of control group 1 and control group 2 (p < 0.05). Conclusion: There is a significant effect of targeted navel drops on diabetic patients in reducing their blood sugar levels, and its curative effect is better than using a single hypoglycemic therapy belonging to western medicine. It can be widely promoted at all levels in medical institutions.

Download Full-text

Anti-diabetic activity of diphenhydramine in diabetic rats

International Journal of Research in Pharmaceutical Sciences ◽

10.26452/ijrps.v11i4.3102 ◽

2020 ◽

Vol 11 (4) ◽

pp. 5067-5070

Author(s):

Pang Jyh Chayng ◽

Nurul Ain ◽

Kaswandi Md Ambia ◽

Rahim Md Noah

Keyword(s):

Blood Glucose ◽

Blood Glucose Level ◽

Glucose Level ◽

Fasting Blood Glucose ◽

Insulin Level ◽

Diabetic Rats ◽

Group Iv ◽

Diabetic Rat ◽

Control Group ◽

Group I

The purpose of this project is to study the anti-diabetic effect of on a diabetic rat model. A total of Twenty male Sprague rats were used and it randomly distributed into four groups which are Group I: , Group II: negative control, Group III: and Group IV: and . In diabetic model were induced with via injection at the dosage of 65mg/kg. and FBG (Fasting Blood Glucose) level of diabetic rats were assessed every three days. Blood was collected via cardiac puncture at day 21 after the induction of treatment. Insulin level of the rats was assessed with the Mercodia Rat Insulin ELISA kit. FBG level of group I (12.16 ±3.96, p<0.05) and group IV (11.34 ±3.67, p<0.05) were significantly decreased. Meanwhile, the for all rats did not show any significant increase. However, the insulin level was escalated in group IV (0.74+0.25, p<0.05) significantly. The present study shows that the and the combination of and lowered blood glucose level and enhanced insulin secretion.

Download Full-text

The Effect of A New Mixture of Sugar and Sugar-Alcohol (Lacritose) on Blood Glucose and Lipids and the Possible Adverse Reactions in Patients with Type 2 Diabetes: A Triple-Blind Randomized Clinical Trial

Journal of Nutrition and Food Security ◽

10.18502/jnfs.v6i4.7620 ◽

2021 ◽

Author(s):

Masoud Rahmanian ◽

Zohreh Mozafari ◽

Danial Chaleshi ◽

Marzieh Shukohifar ◽

Saeedeh Jam-Ashkezari

Keyword(s):

Clinical Trial ◽

Blood Glucose ◽

Randomized Clinical Trial ◽

Fasting Blood Glucose ◽

Resistance Index ◽

Primary Data ◽

Control Group ◽

Diabetic Patients ◽

Diabetes Research

Background: A new sweetener with the commercial name of Lacritose has been recently produced, which is a combination of four simple sugars (lactose, fructose, sucrose, erythritol), with specific ingredients and percentages. This study aimed to assess glycemic response and short term gastrointestinal reactions in type 2 diabetic patients. Methods: In this triple-blind randomized clinical trial, 30 diabetic patients referred to Yazd Diabetes Research Center in 2018 were included. After collecting the primary data, they were assigned into three groups, including sucrose consumers as the control group, sucrose-lactose, and lacritose as the groups of consumers group. They were followed for two weeks, and fasting blood glucose (FBG), 2-hour postprandial test (2HPP), fructose amine, SGOT, SGPT, urea, creatinine, and insulin resistance index (HOMA-IR) were assessed. Results: In lacritose consumers, significant reductions were seen in FBG and 2HPP (P < 0.001 and P = 0.05, respectively), although changes among the groups were not significant. In sucrose-lacritose consumers, FBG and cholesterol levels decreased (P = 0.04 and P = 0.03, respectively). In sucrose consumers, no reduction was seen. HOMA-IR did not significantly decrease, but intergroup changes were obvious. Conclusion: The lacritose effects on FBG and 2HPP were significantly evident, but the other metabolic indices did not show any significant change.

Download Full-text

ASSOCIATION BETWEEN BLOOD LIPID PROFILE AND BLOOD GLUCOSE LEVELS IN MEN WITH CORONARY HEART DISEASE, METABOLIC SYNDROME, AND TYPE 2 DIABETES MELLITUS

CARDIOVASCULAR THERAPY AND PREVENTION ◽

10.15829/1728-8800-2013-5-29-33 ◽

2013 ◽

Vol 12 (5) ◽

pp. 29-33

Author(s):

S. A. Matveeva

Keyword(s):

Blood Glucose ◽

Lipid Profile ◽

Low Density Lipoprotein ◽

Fasting Blood Glucose ◽

Density Lipoprotein ◽

Blood Lipid ◽

Lipoprotein Cholesterol ◽

Blood Lipid Profile ◽

Glucose Levels ◽

Blood Glucose Levels

Aim.To study the associations between blood lipid profile and blood glucose levels in men with coronary heart disease (CHD), stable effort angina (SEA), metabolic syndrome (MS), and Type 2 diabetes mellitus (DM-2).Material and methods.The study included 82 men (mean age 50,5±0,9 years) with CHD, Functional Class I–III SEA, MS, and DM-2. The following lipid profile parameters were assessed: total cholesterol (TCH), triglycerides (TG), low-density lipoprotein cholesterol (LDL–CH), very low-density lipoprotein cholesterol (VLDL–CH), high-density lipoprotein cholesterol (HDL–CH), atherogenic index (AI), and triglyceride index (TGI), together with fasting blood glucose.Results.There were positive (direct) associations between higher levels (>90th percentile) of lipid profile parameters (TCH, TG, LDL–CH, VLDL– CH, HDL–CH, AI, TGI) and blood glucose, as well as between lower levels (≤10th percentile) of lipid profile parameters (TCH, TG, LDL–CH, VLDL– CH, AI, TGI) and blood glucose. At the same time, there were negative (inverse) associations between lower lipid levels (≤10th percentile of TCH, TG, LDL–CH, VLDL–CH, HDL–CH, AI, TGI) and higher glucose levels (>90th percentile), as well as between higher lipid levels (>90th percentile of TCH, TG, LDL–CH, VLDL–CH, HDL–CH, AI, TGI) and lower glucose levels (≤10th percentile).Conclusion.Dyslipidemia and hyperglycemia demonstrate synergetic proatherogenic effects in patients with CHD, SEA, MS, and DM-2, as suggested by significant heterogeneous (direct and inverse) associations between lipid profile parameters and fasting blood glucose. The results obtained provide an opportunity for the assessment of risk levels, prognosis, and need for pharmacological prevention and treatment in patients with combined cardiovascular pathology.

Download Full-text